TERT and neuroblastoma: While some previous panel sequencing studies were analyzing neuroblastomas, these assays were specialized for the detection of non-MYCN-amplified neuroblastomas [32], or genes relevant for risk stratification and the diagnosis of neuroblastomas such as TERT and ATRX were not included in the panel, or the setup of the assay was insufficient to detect chromosomal rearrangements and breakpoint regions [32,33,34].